Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Purpose

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Condition

  • Schizophrenia

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Aged ≥18 years at index date. - Have a confirmed diagnosis of schizophrenia before index date. - Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy. - Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. - Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish). - English or Spanish speaking.

Exclusion Criteria

  • Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening. - Evidence of use of XT prior to time of eligibility screening.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Participants receiving xanomeline and trospium chloride (X/T) therapy
  • Drug: xanomeline and trospium chloride (X/T) therapy
    According to the product label

Recruiting Locations

Boston Medical Center
Boston, Massachusetts 02118
Contact:
Hannah Brown, Site 0002
617-638-8141

More Details

Status
Recruiting
Sponsor
Bristol-Myers Squibb

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com